EP3102609
AÐFERÐIR TIL AÐ FRAMLEIÐA SAMGENA T-FRUMUR SEM ERU NÝTANLEGAR TIL AÐ MEÐHÖNDLA B-FRUMU ILLKYNJUN OG ÖNNUR KRABBAMEIN OG SAMSETNINGAR ÞAR AF
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
4.2.2015EP published:
28.8.2024EP application number:
15746399.3
EP translation filed:
24.10.2024Grant published:
15.11.2024EPO information:
European Patent Register
Max expiry date:
3.2.2035Expiry date:
3.2.2027Next due date:
28.2.2027
Title in English:
METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOFLanguage of the patent:
English
Timeline
Today
4.2.2015EP application
28.8.2024EP Publication
24.10.2024Translation submitted
15.11.2024Registration published
3.2.2027Expires
Owner
Name:
The United States of America, as Represented by The Secretary, Department of Health and Human ServicesAddress:
Office of Technology Transfer National Institutes of Health 6701 Rockledge Drive Suite 700, MSC 7788, Bethesda, Maryland 20892-7788, US
Name:
Kite Pharma, Inc.Address:
2400 Broadway, Santa Monica, CA 90404, US
Inventor
Name:
BETTER, MarcAddress:
Santa Monica, California 90404, US
Name:
FELDMAN, Steven A.Address:
Bethesda, Maryland 20892-1201, US
Name:
ROSENBERG, Steven A.Address:
Bethesda, Maryland 20892-1201, US
Agent
Name:
Zacco Denmark A/SAddress:
Arne Jacobsens Allé 15, DK
Priority
Number:
201461935833 PDate:
4.2.2014Country:
US
Supplementary protection
SPC number:
SPC502
Classification
Categories:
C12N 5/0783, A61K 39/00, A61K 38/17, C07K 14/725, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 16.1.2025
Expires: 3.2.2026
Payer: Árnason Faktor ehf.
Number: 12
Paid: 4.2.2026
Expires: 3.2.2027
Payer: Árnason Faktor ehf.